PT-141 (bremelanotide): the sexual-function peptide, what the trials actually show

PT-141, marketed as bremelanotide under the brand name Vyleesi, is one of the few peptides outside the GLP-1 family with current FDA approval for a sex-difference-relevant indication. The story of how it got there — and what the approval does and doesn't say — is instructive about how a single peptide can have legitimate evidence in one population while remaining experimental in others.

The biology of PT-141

PT-141 (bremelanotide) is a 7-amino-acid peptide derived from alpha-MSH (alpha-melanocyte-stimulating hormone). It binds melanocortin receptors, primarily MC4R (involved in central nervous system regulation of energy balance and sexual function) and to a lesser extent MC3R.^[1]

The melanocortin system has a real role in sexual arousal. MC4R-knockout mice show altered sexual behavior. Pharmacological MC4R activation produces dose-dependent increases in sexual behavior in multiple animal models. The pathway operates in the CNS, upstream of the peripheral mechanisms targeted by PDE5 inhibitors.

This is the mechanistic basis for PT-141's effect: not peripheral vasodilation (the Viagra mechanism) but central modulation of arousal pathways. The clinical implications are different. PDE5 inhibitors help with the mechanical aspect of erection in men who have the desire and arousal. Melanocortin-active drugs work on the desire and arousal aspect itself. Evidence: A for the mechanism.

The HSDD approval

Hypoactive sexual desire disorder (HSDD) in premenopausal women is a real diagnostic entity characterized by persistently low sexual desire causing distress, not better explained by medication, relationship factors, or another medical condition. It's harder to diagnose cleanly than the male ED equivalent and the diagnostic framework has evolved over decades.

Two Phase 3 RCTs (RECONNECT-1 and RECONNECT-2) randomized over 1,200 premenopausal women with HSDD to bremelanotide 1.75 mg subcutaneous as needed or placebo, used over 24 weeks. The primary outcomes were change in desire (measured by validated scales) and change in distress related to low desire. Both endpoints improved modestly but statistically significantly in the bremelanotide arms.^[2] Evidence: A for "PT-141 produces a statistically significant improvement in HSDD-related desire and distress scores."

The effect sizes were modest. The number-needed-to-treat for meaningful clinical benefit is higher than for some other approved drugs. The approval reflects an unmet need (few effective therapies for HSDD) combined with a real but modest effect, not a transformative result.

The FDA approved Vyleesi for HSDD in premenopausal women in 2019.

The off-label landscape

PT-141 in the wellness and men's health context is mostly used off-label for:

• Male erectile dysfunction, particularly when PDE5 inhibitors don't fully address the desire/arousal component
• Female sexual dysfunction beyond HSDD (postmenopausal women, sexual side effects of antidepressants)
• Performance enhancement in people without diagnosed dysfunction

For male ED, there is real Phase 2 evidence. The earlier development program for PT-141 (as intranasal bremelanotide) demonstrated erectile effects in men, including some who hadn't responded to sildenafil. The intranasal formulation was discontinued in part because of blood-pressure spikes at the higher doses needed for the male indication. The subcutaneous formulation that ultimately reached approval is dosed lower; whether the same dose produces meaningful effects in men is partly extrapolation.^[3] Evidence: C for off-label male ED use.

For other off-label uses (postmenopausal women, antidepressant-induced sexual dysfunction, performance enhancement), the evidence is still thinner. Anecdotal reports exist; controlled trials in these populations largely don't.

Side effects and safety

The bremelanotide trials and post-marketing data provide a reasonable safety database for the approved use:

• Nausea is the most common side effect — reported in roughly 40% of users, sometimes leading to discontinuation. Pre-treatment with antiemetics is sometimes used.
• Flushing is common.
• Transient blood pressure rise is documented — typically an increase of 6-8 mmHg systolic peaking 2-4 hours after injection. Patients with uncontrolled hypertension or cardiovascular disease should not use the drug.^[4]
• Headache is common.
• Focal hyperpigmentation — patches of skin darkening, sometimes persistent — is a rare but documented effect, related to melanocortin pathway activation also affecting MC1R in skin.

The safety profile is well-characterized for the approved use case (as-needed dosing, modest doses, monitored patients). Daily or high-dose off-label use is in less-characterized territory, particularly for cumulative cardiovascular and hyperpigmentation risk.^[5]

How PT-141 compares to PDE5 inhibitors

The two are addressing different aspects of sexual function. The wellness conversation that frames PT-141 as "Viagra for women" or "the better Viagra for men" undersells how mechanistically distinct they are. A man with intact desire and mechanical ED is better served by PDE5 inhibitors. A man with low desire and arousal issues is closer to the population PT-141 was originally developed for.^[6]

The gray-market PT-141 problem

PT-141 is sold by research-peptide vendors at significantly lower prices than Vyleesi or compounded versions. The same caveats apply as to any research peptide:

• Unverified purity and identity
• Unverified sterility
• No prescribing oversight
• No monitoring of cardiovascular response
• No screening for contraindications

For PT-141 specifically, the blood-pressure effect makes unmonitored use particularly concerning. A patient with undiagnosed hypertension self-injecting research-grade PT-141 is taking the kind of risk the FDA approval framework specifically warns against.

The practical read

If you're considering PT-141:

1. For HSDD in premenopausal women, Vyleesi has Phase 3 evidence and FDA approval. This is the cleanest path.
2. For off-label male ED, the evidence is older Phase 2 data plus extrapolation. The mechanism plausibly applies, but the dose-response and safety in this population is less mapped.
3. The blood-pressure effect is the most consequential safety consideration. Pre-existing hypertension or cardiovascular disease is a contraindication.
4. Compounded PT-141 with a prescription is a meaningfully better quality category than research-grade PT-141 from gray-market vendors.
5. PT-141 and PDE5 inhibitors are not interchangeable. They address different aspects of sexual function and have different mechanisms.

The honest grade for PT-141 on-label (premenopausal HSDD) is Evidence: A. For off-label male ED, the grade is closer to Evidence: C — there's real older evidence but the development program for the male indication didn't reach approval, and the supporting trials are dated.

FAQ

FDA-approved for what? Premenopausal women with HSDD. Brand name Vyleesi.

Works in men? Real Phase 2 evidence for erectile effects exists from the earlier development program; FDA approval for the male indication was not pursued, largely due to blood-pressure concerns with the intranasal formulation.

Safe? Modest doses in the approved population are well-characterized. Hypertension and cardiovascular disease are contraindications. Unmonitored off-label use is in less-mapped territory.

References

1. 1.Diamond LE, et al. (2004). An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. Journal of Sexual Medicine 1(2):199–211. PMID: 16422975. Link
2. 2.Kingsberg SA, et al. (2019). Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstetrics and Gynecology 134(5):899–908. PMID: 31599840. Link
3. 3.Safarinejad MR, Hosseini SY (2008). Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study. Journal of Urology 179(3):1066–1071. PMID: 18206919. Link
4. 4.Clayton AH, et al. (2016). Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Women's Health 12(3):325–337. PMID: 27181790. Link
5. 5.U.S. Food and Drug Administration (2019). Vyleesi (bremelanotide) approval label. FDA.gov. Link
6. 6.Pfaus J, Giuliano F, Gelez H (2007). Bremelanotide: an overview of preclinical CNS effects on female sexual function. Journal of Sexual Medicine 4 Suppl 4:269–279. PMID: 17958620. Link